Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.63 USD | -2.23% | +4.78% | -19.45% |
Apr. 24 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
Apr. 08 | Gain Therapeutics Names Gene Mack as CFO | MT |
Financials (USD)
Sales 2024 * | 600K | Sales 2025 * | 175K | Capitalization | 47.48M |
---|---|---|---|---|---|
Net income 2024 * | -18M | Net income 2025 * | -28M | EV / Sales 2024 * | 79.1 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 271 x |
P/E ratio 2024 * |
-2.7
x | P/E ratio 2025 * |
-2.19
x | Employees | 31 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.25% |
1 day | -2.23% | ||
1 week | +4.78% | ||
Current month | -10.24% | ||
1 month | -16.51% | ||
3 months | -45.44% | ||
6 months | -2.59% | ||
Current year | -19.45% |
Managers | Title | Age | Since |
---|---|---|---|
Matthias Alder
CEO | Chief Executive Officer | 59 | 21-10-18 |
Eric Richman
BRD | Director/Board Member | 63 | 20-06-30 |
Comptroller/Controller/Auditor | 35 | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dov Goldstein
BRD | Director/Board Member | 56 | 20-12-31 |
Eric Richman
BRD | Director/Board Member | 63 | 20-06-30 |
Matthias Alder
CEO | Chief Executive Officer | 59 | 21-10-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 2.63 | -2.23% | 59,339 |
24-05-16 | 2.69 | +2.67% | 128,638 |
24-05-15 | 2.62 | +11.97% | 151,643 |
24-05-14 | 2.34 | -3.31% | 240,365 |
24-05-13 | 2.42 | -3.59% | 54,674 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.45% | 47.48M | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- GANX Stock